Elixir Pharmaceuticals
Cambridge
About Elixir Pharmaceuticals
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $98.5M
- Funding stage: Late Stage Venture
- Last round: Series D (May 2009)
- Website: elixirpharm.com
- Phone: +1 617-995-7000
Industries & Categories
Biotechnology, Diabetes, Pharmaceutical
Canonical: https://fsome.com/organization/elixir-pharmaceuticals-2741201 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.